Current Ratio
since 2005
Calculation
Eli Lilly & Co., current ratio, long-term trends, calculation
| Current ratio | = | Current assets1 | ÷ | Current liabilities1 | |
|---|---|---|---|---|---|
| Dec 31, 2024 | 1.15 | = | 32,739,700) | ÷ | 28,376,600) |
| Dec 31, 2023 | 0.94 | = | 25,727,000) | ÷ | 27,293,200) |
| Dec 31, 2022 | 1.05 | = | 18,034,500) | ÷ | 17,138,200) |
| Dec 31, 2021 | 1.23 | = | 18,452,400) | ÷ | 15,052,700) |
| Dec 31, 2020 | 1.40 | = | 17,462,100) | ÷ | 12,481,600) |
| Dec 31, 2019 | 1.16 | = | 13,709,600) | ÷ | 11,775,200) |
| Dec 31, 2018 | 1.73 | = | 20,549,600) | ÷ | 11,888,100) |
| Dec 31, 2017 | 1.32 | = | 19,202,100) | ÷ | 14,535,900) |
| Dec 31, 2016 | 1.37 | = | 15,101,400) | ÷ | 10,986,600) |
| Dec 31, 2015 | 1.53 | = | 12,573,600) | ÷ | 8,229,600) |
| Dec 31, 2014 | 1.09 | = | 12,179,800) | ÷ | 11,207,500) |
| Dec 31, 2013 | 1.47 | = | 13,104,700) | ÷ | 8,916,600) |
| Dec 31, 2012 | 1.55 | = | 13,038,700) | ÷ | 8,389,500) |
| Dec 31, 2011 | 1.60 | = | 14,248,200) | ÷ | 8,930,900) |
| Dec 31, 2010 | 2.09 | = | 14,840,000) | ÷ | 7,101,400) |
| Dec 31, 2009 | 1.90 | = | 12,486,500) | ÷ | 6,568,100) |
| Dec 31, 2008 | 0.95 | = | 12,453,300) | ÷ | 13,109,700) |
| Dec 31, 2007 | 2.33 | = | 12,256,900) | ÷ | 5,268,300) |
| Dec 31, 2006 | 1.91 | = | 9,694,400) | ÷ | 5,085,500) |
| Dec 31, 2005 | 1.89 | = | 10,795,800) | ÷ | 5,716,300) |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
1 US$ in thousands
The financial data indicates fluctuations in the liquidity position over the observed annual periods. There are notable trends in current assets, current liabilities, and their relationship as expressed by the current ratio.
- Current Assets
- Current assets demonstrated a general upward trend from 2005 through 2018, with values increasing from approximately 10.8 billion US dollars to over 20.5 billion US dollars. Notable increments occurred especially between 2015 and 2018. However, after peaking in 2018, the figure dropped sharply to about 13.7 billion in 2019, followed by recovery and a subsequent rising trend, reaching around 32.7 billion by 2024. This pattern suggests volatility but strong growth in current assets toward the end of the period.
- Current Liabilities
- Current liabilities showed variability with a significant spike in 2008, rising abruptly to approximately 13.1 billion US dollars before falling back in subsequent years. From 2009 to 2014, current liabilities fluctuated between roughly 6.5 billion and 11.2 billion. Following 2014, there was a generally increasing trend in current liabilities, reaching the highest value of about 28.4 billion by 2024. This steady increase, especially in the later years, indicates growing short-term obligations.
- Current Ratio
- The current ratio exhibited considerable variation, reflecting changes in liquidity. Initially, the ratio remained relatively strong above 1.8 until 2007, then sharply declined to below 1.0 in 2008, indicating potential liquidity stress during that year. Subsequently, it rebounded above 1.5 by 2010 but trended downward to lows near 1.05 by 2018 and dipped further below 1.0 in 2019. In the latest years, the ratio hovered slightly above 1.0, suggesting only marginal coverage of current liabilities by current assets. This trend reflects a changing liquidity profile with periods of stronger and weaker short-term financial health.
Overall, the data reveals periods of both strong liquidity and financial strain. The sharp rises in current liabilities, especially in 2008 and from 2019 onward, combined with fluctuations in current assets, have influenced the current ratio significantly. The marginal current ratios in recent years suggest cautious monitoring is advisable to ensure sufficient short-term asset coverage of obligations moving forward.
Comparison to Competitors
Eli Lilly & Co., current ratio, long-term trends, comparison to competitors
| Eli Lilly & Co. | AbbVie Inc. | Amgen Inc. | Bristol-Myers Squibb Co. | Danaher Corp. | Gilead Sciences Inc. | Johnson & Johnson | Merck & Co. Inc. | Pfizer Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | Vertex Pharmaceuticals Inc. | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dec 31, 2024 | 1.15 | 0.66 | 1.26 | 1.25 | 1.40 | 1.60 | 1.11 | 1.36 | 1.17 | 4.73 | 1.66 | 2.69 |
| Dec 31, 2023 | 0.94 | 0.87 | 1.65 | 1.43 | 1.68 | 1.43 | 1.16 | 1.25 | 0.91 | 5.69 | 1.75 | 3.99 |
| Dec 31, 2022 | 1.05 | 0.96 | 1.41 | 1.25 | 1.89 | 1.29 | 0.99 | 1.47 | 1.22 | 5.06 | 1.48 | 4.83 |
| Dec 31, 2021 | 1.23 | 0.79 | 1.59 | 1.52 | 1.43 | 1.27 | 1.35 | 1.27 | 1.40 | 3.56 | 1.50 | 4.46 |
| Dec 31, 2020 | 1.40 | 0.84 | 1.81 | 1.58 | 1.86 | 1.40 | 1.21 | 1.02 | 1.35 | 3.63 | 2.13 | 4.33 |
| Dec 31, 2019 | 1.16 | 3.18 | 1.44 | 1.60 | 5.19 | 3.10 | 1.26 | 1.24 | 0.88 | 3.67 | 1.92 | 3.61 |
| Dec 31, 2018 | 1.73 | 0.98 | 2.79 | 1.61 | 1.47 | 3.38 | 1.47 | 1.17 | 1.57 | 4.47 | 1.73 | 3.43 |
| Dec 31, 2017 | 1.32 | 1.28 | 5.49 | 1.55 | 1.43 | 2.74 | 1.41 | 1.33 | 1.35 | 3.82 | 1.34 | 3.28 |
| Dec 31, 2016 | 1.37 | 1.65 | 4.11 | 1.55 | 0.97 | 2.22 | 2.47 | 1.78 | 1.25 | 2.56 | 1.44 | 2.31 |
| Dec 31, 2015 | 1.53 | 1.50 | 4.44 | 1.30 | 1.27 | 2.50 | 2.17 | 1.55 | 1.49 | 3.59 | 1.38 | 2.78 |
| Dec 31, 2014 | 1.09 | 1.41 | 4.95 | 1.73 | 1.75 | 3.07 | 2.36 | 1.77 | 2.67 | 3.31 | 1.22 | 4.20 |
| Dec 31, 2013 | 1.47 | 2.59 | 3.44 | 1.52 | 2.01 | 1.15 | 2.20 | 2.00 | 2.41 | 6.01 | 3.16 | 3.99 |
| Dec 31, 2012 | 1.55 | 2.27 | 3.81 | 1.15 | 1.80 | 1.44 | 1.90 | 1.90 | 2.15 | 7.37 | 2.31 | 3.67 |
| Dec 31, 2011 | 1.60 | — | 4.80 | 1.97 | 1.50 | 5.53 | 2.38 | 2.04 | 2.06 | 4.40 | 1.55 | 3.39 |
| Dec 31, 2010 | 2.09 | — | 3.52 | 1.97 | 1.73 | 2.32 | 2.05 | 1.86 | 2.11 | 3.28 | 2.42 | 2.23 |
| Dec 31, 2009 | 1.90 | — | 4.89 | 2.21 | 1.89 | 2.57 | 1.82 | 1.80 | 1.66 | 4.55 | 2.76 | 4.59 |
| Dec 31, 2008 | 0.95 | — | 3.12 | 2.20 | 1.53 | 3.52 | 1.65 | 1.35 | 1.59 | 6.23 | 2.82 | 4.01 |
| Dec 31, 2007 | 2.33 | — | 2.11 | 1.20 | 1.40 | 4.11 | 1.51 | 1.23 | 2.15 | 2.81 | 1.93 | 2.49 |
| Dec 31, 2006 | 1.91 | — | 1.67 | 1.59 | 1.38 | 3.18 | 1.20 | 1.20 | 2.20 | 10.44 | 1.70 | 3.07 |
| Dec 31, 2005 | 1.89 | — | 2.57 | 1.78 | 1.30 | 6.79 | 2.48 | 1.58 | 1.47 | 8.46 | 1.71 | 3.84 |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)
Eli Lilly & Co., current ratio, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)
| Eli Lilly & Co. | Pharmaceuticals, Biotechnology & Life Sciences | |
|---|---|---|
| Dec 31, 2024 | 1.15 | 1.24 |
| Dec 31, 2023 | 0.94 | 1.27 |
| Dec 31, 2022 | 1.05 | 1.30 |
| Dec 31, 2021 | 1.23 | 1.36 |
| Dec 31, 2020 | 1.40 | 1.37 |
| Dec 31, 2019 | 1.16 | 1.66 |
| Dec 31, 2018 | 1.73 | 1.71 |
| Dec 31, 2017 | 1.32 | 1.74 |
| Dec 31, 2016 | 1.37 | 1.91 |
| Dec 31, 2015 | 1.53 | 1.90 |
| Dec 31, 2014 | 1.09 | 2.19 |
| Dec 31, 2013 | 1.47 | 2.17 |
| Dec 31, 2012 | 1.55 | 2.04 |
| Dec 31, 2011 | 1.60 | 2.30 |
| Dec 31, 2010 | 2.09 | 2.14 |
| Dec 31, 2009 | 1.90 | 1.95 |
| Dec 31, 2008 | 0.95 | 1.66 |
| Dec 31, 2007 | 2.33 | 1.74 |
| Dec 31, 2006 | 1.91 | 1.65 |
| Dec 31, 2005 | 1.89 | 1.82 |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Industry (Health Care)
Eli Lilly & Co., current ratio, long-term trends, comparison to industry (health care)
| Eli Lilly & Co. | Health Care | |
|---|---|---|
| Dec 31, 2024 | 1.15 | 1.14 |
| Dec 31, 2023 | 0.94 | 1.17 |
| Dec 31, 2022 | 1.05 | 1.19 |
| Dec 31, 2021 | 1.23 | 1.24 |
| Dec 31, 2020 | 1.40 | 1.24 |
| Dec 31, 2019 | 1.16 | 1.40 |
| Dec 31, 2018 | 1.73 | 1.45 |
| Dec 31, 2017 | 1.32 | 1.49 |
| Dec 31, 2016 | 1.37 | 1.67 |
| Dec 31, 2015 | 1.53 | 1.66 |
| Dec 31, 2014 | 1.09 | 1.87 |
| Dec 31, 2013 | 1.47 | 1.93 |
| Dec 31, 2012 | 1.55 | 1.81 |
| Dec 31, 2011 | 1.60 | 1.92 |
| Dec 31, 2010 | 2.09 | 1.80 |
| Dec 31, 2009 | 1.90 | 1.75 |
| Dec 31, 2008 | 0.95 | 1.42 |
| Dec 31, 2007 | 2.33 | 1.51 |
| Dec 31, 2006 | 1.91 | 1.39 |
| Dec 31, 2005 | 1.89 | 1.64 |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).